New chemo cocktail aims to boost pancreatic cancer surgery success
NCT ID NCT06821997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a chemotherapy combination called NALIRIFOX given before surgery to people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough to allow successful removal and reduce the chance of the cancer coming back. The study will enroll 20 participants and measure how many have a major response in the tumor tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NALIRIFOX (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin)
- What this could lead to
- If successful, this approach could make surgery more effective and lower the chance of cancer returning in patients with borderline resectable pancreatic cancer.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The chemotherapy combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene test may guide smarter chemo for pancreatic cancer
- Could a special MRI help doctors better treat pancreatic cancer?
- Triple attack on pancreatic cancer: radiotherapy, chemo, and immunotherapy aim to make tumors removable
- New drug targets pancreatic cancer before surgery
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- Genetic test may guide chemo choice for pancreatic cancer patients